Atea Pharmaceuticals, Inc. (AVIR) vs REGENXBIO Inc. (RGNX)
A side-by-side comparison of Atea Pharmaceuticals, Inc. and REGENXBIO Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVIR
Atea Pharmaceuticals, Inc.
$5.04HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
RGNX
REGENXBIO Inc.
$7.55HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
Total return — AVIR vs RGNX
growth of $100 · dividends reinvested · last 6yAVIR -83.1% (-25.6%/yr)RGNX -73.0% (-19.6%/yr)RGNX compounded faster over this window
AVIR RGNX
AVIR vs RGNX: by the numbers
- •AVIR is the larger company ($403M vs $390M market cap).
- •Both run net losses; AVIR's is the smaller (0.00% vs -112.58% net margin).
Metrics side by side
Valuation
| Metric | AVIR | RGNX |
|---|---|---|
| P/S ratio | N/A | 2.24 |
| P/B ratio | 1.98 | 5.44 |
Profitability
| Metric | AVIR | RGNX |
|---|---|---|
| Gross margin | 0.00% | 88.09% |
| Operating margin | 0.00% | -94.08% |
| Net margin | 0.00% | -112.58% |
| ROE | -80.96% | -273.72% |
| ROIC | -89.93% | -54.00% |
Growth (annualized)
| Metric | AVIR | RGNX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 1.59% |
| Total return CAGR (5Y) | -34.44% | -24.15% |
Frequently asked
- How have AVIR and RGNX total returns compared?
- Over the past 5 years, AVIR delivered -34.44% and RGNX delivered -24.15% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.